Aliskiren and Muscle Sympathetic Nerve Activity

• Status: Unknown status
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The central hypothesis of this project is that Aliskiren causes a substantial decrease in MSNA in hypertensive patients with CKD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UMC Utrecht

Criteria

Inclusion Criteria:

• Patients with stable chronic kidney disease and hypertension: i.e. using antihypertensive drugs and/or blood pressure > 145/90 mmHg when off medication.

• Patients on ACE inhibitor or ARB

Exclusion Criteria:

• Patients with diabetes mellitus

• Patients on renal replacement therapy

• Pregnant patients Using of antihypertensive which cannot be stopped

• Patients on immunosuppressive therapy and active nephrotic syndrome